AstraZeneca (AZN) Stock Rises as Oncology Sales Drive Q2 Beat
TLDR
- Q2 total revenue came in at $15.38 billion, up 5% at constant currency
- Core EPS rose 18% to $2.63, beating the analyst consensus of $2.48
- Oncology revenue grew 15% at constant currency, offsetting declines in other units
- AZN reiterated its 2030 target of $80 billion in annual revenue
- A late-stage Ultomiris study failed to meet its primary goal; Wainua also missed earlier this month
AstraZeneca stock was up around 1.6% in early trading on Monday after the company posted second-quarter results that came in ahead of expectations.
Total revenue for the quarter reached $15.38 billion, compared to $14.46 billion in the same period last year. That works out to a 5% increase at constant currency. Analysts had been looking for $15.39 billion, so it was essentially in line on the top line.
๐จ $AZN (AstraZeneca) Q2 2026 Earnings
Beat expectationsโฆ
but pipeline concerns after trial failure are the real story ๐________________________________________
๐ KEY METRICS (Q2 2026)
๐น Core EPS: $2.63 (+18% YoY) ๐ข
๐น Consensus EPS: $2.48 โ **beat**
๐นโฆโฆ Continue reading the full article at the original source below.
